Compare Citius Pharmaceuticals Inc (CTXR) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs QUALCOMM, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while QUALCOMM, Inc. trades at $178.78 (market cap $187.72B). The key difference: QUALCOMM, Inc. is far larger — about 12822.4× Citius Pharmaceuticals Inc's market cap, and QUALCOMM, Inc. pays a 2.07% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | QCOM | |
|---|---|---|
Market Cap | $14.64M | $187.72B |
Sector | Health | Technology |
52-Week High | $1.82 | $251.10 |
52-Week Low | $0.53 | $124.07 |
Enterprise Value | $10.86M | $193.19B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Qualcomm (QCOM) trades at $183.98, down 2.74% on the day, amid a bearish technical signal. The company maintains strong profitability with 54.8% gross margins and 22.31% net income margin, though revenue growth has been modest. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.56 estimate. Analyst consensus remains positive with a $222.53 price target, representing 21% upside potential from current levels.
Qualcomm faces near-term headwinds from smartphone market softness but is successfully diversifying into automotive and AI data centers. The stock offers value at 19.15x P/E with strong cash flow generation, though competition from Nvidia in PC chips presents execution risk. With 42.65% of analysts rating it Buy and solid balance sheet fundamentals, QCOM presents a compelling long-term opportunity despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
